Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Weiss, Roger
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Roger Douglas Weiss, M.D.
Title
Professor of Psychiatry
Institution
McLean Hospital
Department
Psychiatry
Address
Mclean Hospital
Psychiatry
115 Mill St
Belmont MA 02478
Phone
617/855-2242
Fax
617/855-2699
vCard
Download vCard
(
login for email
)
research activities and funding
|
selected publications
|
Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can
login
to make corrections and additions.
Most Recent
|
List All
R21DA041682
(CHAN, KEVIN E)
Mar 15, 2017 - Feb 28, 2019
NIH
Opioid Use and Abuse in the Dialysis Population
Role: Co-Principal Investigator
K24DA022288
(WEISS, ROGER D.)
Apr 1, 2007 - Mar 1, 2019
NIH
Mentoring in drug abuse and dual diagnosis research
Role: Principal Investigator
UG1DA015831
(D'ONOFRIO, GAIL)
Sep 30, 2002 - Feb 28, 2025
NIH
The National Drug Abuse Clinical Trials Network: New England Consortium Node
Role: Co-Principal Investigator
U10DA015831
(WEISS, ROGER D.)
Sep 30, 2002 - Aug 31, 2015
NIH
The National Drug Abuse Treatment Clinical Trials Network (U10)
Role: Co-Principal Investigator
R01DA015968
(WEISS, ROGER D.)
Sep 30, 2002 - Jan 31, 2009
NIH
Modifying Group Therapy for Bipolar Abusers
Role: Principal Investigator
U10AA011756
(WEISS, ROGER D.)
Sep 30, 1997 - Aug 31, 2007
NIH
Behavioral and Pharmacologic Treatment of Alcoholism
Role: Principal Investigator
K02DA000326
(WEISS, ROGER D.)
Apr 20, 1997 - Mar 31, 2007
NIH
Treatment of Drug Dependence and Psychiatric Illness
Role: Principal Investigator
R01DA009400
(WEISS, ROGER D.)
Sep 30, 1994 - Dec 31, 2003
NIH
RELAPSE PREVENTION GROUP FOR BIPOLAR SUBSTANCE ABUSERS
Role: Principal Investigator
U01DA007693
(WEISS, ROGER D.)
Sep 30, 1991 - Jul 31, 2000
NIH
PSYCHOSOCIAL TREATMENT OF COCAINE USE DISORDER
Role: Principal Investigator
U18DA007693
(WEISS, ROGER D.)
Sep 30, 1991 - Aug 31, 1995
NIH
PSYCHOSOCIAL TREATMENT OF COCAINE USE DISORDER
Role: Principal Investigator
R29DA005944
(WEISS, ROGER D.)
Aug 1, 1989 - Jul 31, 1995
NIH
PREDICTORS OF OUTCOME IN COCAINE DEPENDENCE
Role: Principal Investigator
S07RR005484
(COLE, JONATHAN O)
Apr 1, 1979 - Sep 29, 1992
NIH/NCRR
COURSE OF DYSKINESIA
Role: Co-Principal Investigator
Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
Newest
|
Oldest
|
Most Cited
|
Most Discussed
|
Timeline
|
Field Summary
|
Plain Text
PMC Citations
indicate the number of times the publication was cited by articles in PubMed Central, and the
Altmetric
score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.)
Fields
are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation
tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW, Kampman KM, Pravetoni M, Preston KL, Vandrey R, Bergeria CL, Bogenschutz MP, Brown RT, Dunn KE, Dworkin RH, Finan PH, Hendricks PS, Houtsmuller EJ, Kosten TR, Lee DC, Levin FR, McRae-Clark A, Raison CL, Rasmussen K, Turk DC,
Weiss RD
, Strain EC. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023 01 01; 80(1):84-92.
PMID:
36449315
.
Citations:
Fields:
Psy
Psychiatry
Psy
Psychology
Translation:
Humans
Pan Y, Feaster DJ, Odom G, Brandt L, Hu MC,
Weiss RD
, Rotrosen J, Saxon AJ, Luo SX, Balise RR. Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. Drug Alcohol Depend Rep. 2022 Dec; 5.
PMID:
36644227
; PMCID:
PMC9838120
.
Citations:
Schuman-Olivier Z
, Fatkin T, Creedon TB, Samawi F, Moore SK, Okst K, Fredericksen AK, Oxnard AS,
Roll D
, Smith L, Cook BL,
Weiss RD
. Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study. Am J Addict. 2022 Dec 05.
PMID:
36470641
.
Citations:
Fields:
Sub
Substance-Related Disorders
McCarthy JM
, Wood AJ, Shinners MG, Heinrich H,
Weiss RD
, Mueser KT, Meyers RJ,
Carol EE
,
Hudson JI
, Öngür D. Pilot development and feasibility of telehealth Community Reinforcement and Family Training (CRAFT) for early psychosis and substance use. Psychiatry Res. 2022 11; 317:114804.
PMID:
36030701
.
Citations:
Fields:
Psy
Psychiatry
Translation:
Humans
Kleinman RA, Nielsen S,
Weiss RD
. Is daily supervised buprenorphine-naloxone dosing necessary? BMJ. 2022 08 16; 378:e071467.
PMID:
35973725
.
Citations:
2
Fields:
Med
Medicine (General)
Translation:
Humans
Provost SE
,
Griffin ML
, Hilton BT,
McHugh RK
, Taghian NR, Trinh CD,
Weiss RD
. Correlates of optimism among patients in substance use disorder inpatient treatment. Am J Addict. 2022 11; 31(6):494-501.
PMID:
35975406
.
Citations:
Fields:
Sub
Substance-Related Disorders
Translation:
Humans
Suzuki J
, Martin B, Prostko S,
Chai PR
,
Weiss RD
. Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study. Integr Med Rep. 2022 Aug 01; 1(1):157-163.
PMID:
36105269
.
Citations:
Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI,
McHugh RK
, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE,
Weiss RD
, Wu LT. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022 09; 117(9):2438-2447.
PMID:
35293064
; PMCID:
PMC9543602
.
Citations:
Fields:
Sub
Substance-Related Disorders
Kleinman RA,
Weiss RD
. Benzodiazepine-Involved Overdose Deaths in the USA: 2000-2019. J Gen Intern Med. 2022 06; 37(8):2103-2109.
PMID:
35415793
; PMCID:
PMC9198172
.
Citations:
Fields:
Int
Internal Medicine
Translation:
Humans
Weiner SG
, Hendricks MA, El Ibrahimi S, Ritter GA, Hallvik SE, Hildebran C,
Weiss RD
,
Boyer EW
, Flores DP, Nelson LS, Kreiner PW, Fischer MA. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone. PLoS One. 2022; 17(4):e0266561.
PMID:
35381052
; PMCID:
PMC8982846
.
Citations:
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Connery HS
,
Weiss RD
,
Griffin ML
, Trinh CD, Kim J, Rockett IRH,
McHugh RK
. Suicidal motivations among opioid overdose survivors: Replication and extension. Drug Alcohol Depend. 2022 06 01; 235:109437.
PMID:
35427980
; PMCID:
PMC9106902
.
Citations:
Fields:
Sub
Substance-Related Disorders
Translation:
Humans
McHugh RK
, Chase A, Trinh CD,
Weiss RD
. Are Pain and Negative Affect Coping Distinct Motives for Opioid Misuse? Subst Use Misuse. 2022; 57(6):848-852.
PMID:
35258408
; PMCID:
PMC9069863
.
Citations:
Fields:
Sub
Substance-Related Disorders
Translation:
Humans
Copersino ML
, Slayter E,
McHugh RK
,
Shedlack KJ
,
Lukas SE
,
Weiss RD
. Clinical utility of a hybrid secondary and relapse prevention program in adults with mild intellectual disability or borderline intellectual functioning in community residential and day habilitation settings. Disabil Health J. 2022 06; 15(2S):101293.
PMID:
35337784
.
Citations:
Fields:
Hea
Health Services
Phy
Physical and Rehabilitation Me
Pub
Public Health
Translation:
Humans
PH
Public Health
Weiner SG
, El Ibrahimi S, Hendricks MA, Hallvik SE, Hildebran C, Fischer MA,
Weiss RD
,
Boyer EW
, Kreiner PW, Wright DA, Flores DP, Ritter GA. Factors Associated With Opioid Overdose After an Initial Opioid Prescription. JAMA Netw Open. 2022 01 04; 5(1):e2145691.
PMID:
35089351
; PMCID:
PMC8800077
.
Citations:
1
Fields:
Med
Medicine (General)
Translation:
Humans
McHugh RK
, Hilton BT, Chase AM,
Griffin ML
,
Weiss RD
. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine? Drug Alcohol Depend. 2021 11 01; 228:109084.
PMID:
34607194
; PMCID:
PMC8595708
.
Citations:
Fields:
Sub
Substance-Related Disorders
Translation:
Humans
Sugarman DE
,
Busch AB
,
McHugh RK
,
Bogunovic OJ
, Trinh CD,
Weiss RD
,
Greenfield SF
. Patients' perceptions of telehealth services for outpatient treatment of substance use disorders during the COVID-19 pandemic. Am J Addict. 2021 09; 30(5):445-452.
PMID:
34405475
.
Citations:
3
Fields:
Sub
Substance-Related Disorders
Translation:
Humans
PH
Public Health
Strain EC, Kampman KM,
Weiss RD
. Moving Beyond Medications That Act at the µ Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry. 2021 07 01; 78(7):701-702.
PMID:
33851964
.
Citations:
Fields:
Psy
Psychiatry
Psy
Psychology
Translation:
Humans
Hilton BT,
Yusufov M
, Rosellini AJ, Taghian NR,
Weiss RD
,
Griffin ML
,
McHugh RK
. Psychometric properties of the Anxiety Sensitivity Index-3 in adults with substance use disorders. J Subst Abuse Treat. 2022 01; 132:108507.
PMID:
34214925
.
Citations:
Fields:
Sub
Substance-Related Disorders
Translation:
Humans